It is precisely because of the Keynote-224 (Zhu et al., 2018) research results that in 2018, the FDA approved pembrolizumab for the second-line treatment of advanced HCC patients, and the second PD-1 inhibitor approved by FDA for advanced HCC. This evidence concerns the gene RPL17 and hepatocellular carcinoma.